This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
Current Atherosclerosis Reports Open Access 01 January 2022
-
One drug to treat many diseases: unlocking the economic trap of rare diseases
Metabolic Brain Disease Open Access 14 September 2020
-
Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1
Retrovirology Open Access 01 October 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. After Glybera's withdrawal, what's next for gene therapy?. Nat Biotechnol 35, 491–492 (2017). https://doi.org/10.1038/nbt0617-491
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0617-491
This article is cited by
-
Selection of appropriate non-clinical animal models to ensure translatability of novel AAV-gene therapies to the clinic
Gene Therapy (2024)
-
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
Current Atherosclerosis Reports (2022)
-
The current landscape of nucleic acid therapeutics
Nature Nanotechnology (2021)
-
Individualized therapy trials: navigating patient care, research goals and ethics
Nature Medicine (2021)
-
Gene therapy: a double-edged sword with great powers
Molecular and Cellular Biochemistry (2020)